Take the guesswork out of HF care

  • Provides total blood and red blood cell volume along with calculated patient-specific ideals*
  • Actionable results—quantifies the excess or deficit with 98% accuracy
  • Confidently identify and address anemia, regardless of plasma expansion or depletion
  • Non-invasive, single-venipuncture technique
  • Over 40,000 tests performed in over 75 hospitals
  • Fully reimbursed by Medicare

Lower real-world heart failure mortality and readmissions with individualized care guided by direct blood volume analysis (BVA)

In a large mixed (HFpEF/HFrEF) cohort (n=245), individualized management guided by BVA improved key outcomes vs 10:1 propensity score matched-controls:

Propensity-score control matching analysis was performed for 245 consecutive HF admissions to a community hospital (Sept 2007–Apr 2014, age 78±10 yrs, HFrEF 50%, Stage 4 CKD 30%). Total blood volume (TBV) and red blood cell volume (RBCV) were measured at admission by an I-131 labeled albumin indicator-dilution technique [Daxor BVA-100]. Decongestion strategy targeted TBV to 6%-8% above patient-specific norm. Anemia was corrected with iron, epoetin, and/or packed red blood cells. Controls derived from CMS data were matched 10:1 for demographics, comorbidity, and year of treatment.1

Volume and red blood cell status heterogeneity was high, suggesting a medical need for the direct, accurate evaluation only possible with BVA.

  • The high heterogeneity observed in this cohort is consistent with previously published observational data in HF for total blood volume2-4 and red blood cell volume2,4-6 status

BVA touchpoints

Points of contact in HF care at which to consider direct BVA


The extent, composition and distribution of volume overload in decompensated heart failure are highly variable, and this variability needs to be taken into account in the approach to individualized therapy.“2

- Wayne L.Miller, M.D.

  • *Derived from Metropolitan Life height, weight, and gender data in a uniquely accurate, validated methodology.7,8

    † A 131I labeled albumin tracer injection (≥25 microcuries: no requirement for thyroid blockade9) is followed by 5 blood draws 5-6 minutes apart. The Daxor BVA-100 measures plasma dilution in successive samples and performs a regression analysis to arrive at the total blood volume. Institutional procedural variance drives a real-world time range of ~45-90 minutes for full results; preliminary results may be obtained in <30 minutes.

    References: 1. Strobeck JE, et al. Propensity Score Matched-Controlled Study of Impact of Blood Volume Quantification on Decongestion Strategy, Readmission Rates, and Mortality in Hospitalized Heart Failure Patients. Poster presented at American College of Cardiology 67th Annual Scientific Session; March 2018; Orlando, FL; abstract 1105-104. 2. Miller WL, et al. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management. J Am Coll Cardiol HF 2014;2:298-305. 3. Androne AS, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004;93:1254-1259. 4. Miller WL, et al. Volume overload profiles in patients with preserved and reduced ejection fraction chronic heart failure: is there a difference? J Am Coll Cardiol HF 2016;4:453-459. 5. Miller WL, et al. Peripheral venous hemoglobin and red blood cell mass mismatch in volume overload systolic heart failure: implications for patient management. J Cardiovasc Trans Res 2015;8:404-410. 6. Androne AS, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-229. 7. Feldschuh J, et al. Prediction of the normal blood volume—relation of blood volume to body habitus. Circulation 1977;56(4):605-612. 8. Feldschuh J, et al. The importance of correct norms in blood volume measurement. Am J Med Sci 2007;334(1):41-46. 9. Volumex® [package insert]. Daxor Corporation, New York, NY; 2005.